Banuchi Victoria E, Dooley Laura, Lee Nancy Y, Pfister David G, McBride Sean, Riaz Nadeem, Bilsky Mark H, Ganly Ian, Shah Jatin P, Kraus Dennis H, Morris Luc G T
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, U.S.A.
North Shore-Long Island Jewish Cancer Institute, New York, New York, U.S.A.
Laryngoscope. 2016 Jul;126(7):1556-61. doi: 10.1002/lary.25862. Epub 2016 Feb 10.
OBJECTIVES/HYPOTHESIS: To define the incidence and risk factors of metastatic disease and the effectiveness of salvage therapy in esthesioneuroblastoma (ENB).
Retrospective analysis of 57 patients presenting from 1979 through 2009.
Cumulative incidence of neck failure, distant failure, and survival were assessed using the Kaplan-Meier method.
Overall survival for all patients was 85% at 5 years and 75% at 10 years. Overall survival was negatively impacted by intracranial tumor extension (P < 0.001), positive resection margins (P = 0.05), and neck metastases (P = 0.017). Neck lymph nodes were not routinely electively irradiated during this time period. Nodal metastases developed in 17% of patients at a median time of 60 months. Kadish stage was not associated with a risk of nodal metastasis (P = 0.78). After treatment for nodal recurrence, locoregional control was achieved in 78% of patients. Of patients developing nodal recurrence, more than half developed distant metastases. The cumulative incidence of distant metastasis was 39% at a median time of 40 months. Patients who presented with Kadish stage C or D had a significantly increased risk of distant failure (P < 0.001). In patients developing nodal (P = 0.017) or distant metastasis (P = 0.001), the probability of survival was significantly decreased.
Regional and distant metastases in patients with esthesioneuroblastoma occur in a delayed fashion and negatively impact survival. Neck nodal recurrence may be a harbinger of distant metastases. At the Memorial Sloan Kettering Cancer Center, New York, New York, we now treat the majority of ENB patients with elective nodal irradiation. However, the chief obstacle to long-term cure is distant metastases.
目的/假设:明确嗅神经母细胞瘤(ENB)转移疾病的发病率、危险因素及挽救性治疗的有效性。
对1979年至2009年就诊的57例患者进行回顾性分析。
采用Kaplan-Meier法评估颈部失败、远处失败及生存的累积发生率。
所有患者5年总生存率为85%,10年为75%。颅内肿瘤扩展(P < 0.001)、手术切缘阳性(P = 0.05)和颈部转移(P = 0.017)对总生存有负面影响。在此期间,颈部淋巴结未常规进行选择性照射。17%的患者出现淋巴结转移,中位时间为60个月。Kadish分期与淋巴结转移风险无关(P = 0.78)。淋巴结复发经治疗后,78%的患者实现了局部区域控制。出现淋巴结复发的患者中,超过一半发生了远处转移。远处转移的累积发生率为39%,中位时间为40个月。表现为Kadish C期或D期的患者远处失败风险显著增加(P < 0.001)。发生淋巴结转移(P = 0.017)或远处转移(P = 0.001)的患者,生存概率显著降低。
嗅神经母细胞瘤患者的局部和远处转移出现较晚,对生存有负面影响。颈部淋巴结复发可能是远处转移的先兆。在纽约市纪念斯隆凯特琳癌症中心,我们现在对大多数ENB患者进行选择性淋巴结照射治疗。然而,长期治愈的主要障碍是远处转移。
4。《喉镜》,2016年,第126卷,第1556 - 1561页